Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jul 3, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Optimizing Hepatitis C Virus Antibody Testing Strategy and Setting: Results From a Large Real-World Screening

Grishma Hirode1, Camelia Capraru1, Aaron Vanderhoff1

  • 1Toronto Centre for Liver Disease/Viral Hepatitis Care Network (VIRCAN), University Health Network, Toronto, Ontario, Canada.

Open Forum Infectious Diseases
|July 2, 2026
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Single-Use vs Reusable Catheters for Intermittent Catheterization in Patients With Urinary Retention: The COMPARE Randomized Clinical Trial.

JAMA network open·2026
Same author

Association of FUT2 rs601338 Genotype with Colonic Mucosal Microbiome Composition, Post-Transplant Bacteremia, and All-Cause Mortality After Liver Transplantation for Primary Sclerosing Cholangitis: A Retrospective Cohort Study.

Journal of clinical medicine·2026
Same author

A Gender-Based Descriptive Analysis of the Canadian Network Undertaking Against Hepatitis C (CANUHC) Cohort From 2015-2023.

Open forum infectious diseases·2026
Same author

Bezafibrate for Primary Biliary Cholangitis: a Number Needed to Treat Analysis.

JHEP reports : innovation in hepatology·2026
Same author

Hepatitis C virus infection dynamics, treatment, and lipid nanoparticle-mediated infection in humanized liver chimeric mouse models.

Science advances·2026
Same author

Rapid hepatitis C test and treat with peer support at opioid treatment programs (RAPID HCV): a hybrid effectiveness-implementation type 1 randomized control trial.

Lancet regional health. Americas·2026
Same journal

Defining Success and Failure In Prosthetic Joint Infections: A Meta-epidemiologic Study Toward A Core Outcome Set.

Open forum infectious diseases·2026
Same journal

A Call to Investigate the Association Between Histoplasmosis and Fatigue.

Open forum infectious diseases·2026
Same journal

Influenza Vaccines for Persons Who Are Immunocompromised: A Scoping Review of the Literature.

Open forum infectious diseases·2026
Same journal

Mpox Disease Severity Reduced in Intradermally MVA-BN Vaccinated Compared to Unvaccinated Patients in Sweden: A Retrospective 2024-2025 Observational Case-series.

Open forum infectious diseases·2026
Same journal

Persistent Dominance of Serotype 3 in Noninvasive Pneumococcal Disease in Belgium (2022-2025).

Open forum infectious diseases·2026
Same journal

Cryptococcal Meningitis: Comparison of Short- (≤ 1 Week) Versus Longer-duration (> 1 Week) Liposomal Amphotericin B Induction Therapy and Factors Associated With Clinical Outcomes in HIV and Non-HIV Patients.

Open forum infectious diseases·2026
See all related articles
Summary
This summary is machine-generated.

Optimal hepatitis C virus (HCV) screening is crucial for elimination. This study shows that while some patients are lost during the care cascade, treatment initiation is high, especially when matching HCV antibody testing to the right setting.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Public Health

Background:

  • Optimal hepatitis C virus (HCV) screening is essential for preventing transmission and achieving global elimination targets.
  • Administrative data offers insights into testing and treatment trends, but understanding care cascade barriers requires more detailed information.
  • A real-world analysis was conducted to document the HCV care cascade and evaluate the effectiveness of different HCV antibody (Ab) screening methods across various settings.

Purpose of the Study:

  • To document the hepatitis C virus (HCV) care cascade in a real-world setting.
  • To evaluate the effectiveness of different HCV antibody (Ab) screening modalities across diverse community and clinical environments.
  • To identify barriers and facilitators in the HCV care cascade for individuals undergoing testing.
Keywords:
barrierscascadehepatitis Cprevalencereal-world

More Related Videos

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Related Experiment Videos

Last Updated: Jul 3, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System
05:55

Identifying Inhibitors of the HBx-DDB1 Interaction Using a Split Luciferase Assay System

Published on: December 21, 2019

Main Methods:

  • A cross-sectional study was performed involving individuals who underwent HCV Ab testing.
  • Data was collected from participating centers in Ontario, Canada, between May 2010 and June 2023.
  • The study analyzed the care cascade from HCV Ab positivity through RNA testing, follow-up, treatment initiation, completion, and sustained virologic response.

Main Results:

  • HCV Ab prevalence was 13.6% among 61,605 tested individuals, peaking in the 35-44 age group (23.2%) and at addiction clinics (41.0%).
  • Among HCV Ab-positive individuals, 79.7% had RNA testing, with 57.3% testing positive.
  • Linkage to care was most effective when HCV Ab testing was conducted in primary care settings, with high rates of treatment initiation (61.1% of RNA-positive) and completion (47.3% of RNA-positive).

Conclusions:

  • Despite some attrition in the HCV care cascade, treatment initiation rates were higher than administrative data suggested.
  • Utilizing multiple HCV testing modalities is beneficial.
  • Matching the optimal HCV antibody testing modality to the specific clinical or community setting enhances linkage to care pathways.